Garcia Marino 4

What Happened

• Garcia Marino, CEO, President and a director of Dianthus Therapeutics (DNTH), received a derivative equity award of 355,000 shares on 2026-02-03. The grant is reported at a $0.00 acquisition price (no cash paid at grant); the Form 4 shows a reported value of $0 for the award itself.

Key Details

• Transaction date: 2026-02-03; Form 4 filed 2026-02-04 (timely).
• Transaction type/code: Grant / Award (derivative interest).
• Quantity: 355,000 shares underlying the award; reported acquisition price $0.00.
• Shares owned after transaction: not specified in the provided filing.
• Footnote: award vests in equal monthly installments over four years after January 1, 2026, subject to continued service.
• No 10b5-1 plan, tax withholding, or immediate sale reported in this filing.

Context

• This is a compensation grant (a derivative award subject to vesting), not an open-market purchase or sale. Such grants are common as executive compensation and do not by themselves indicate buying or selling for cash or an immediate change in share ownership until vesting occurs.